Healogics draws $240M investment
By HME News Staff
Updated 9:00 AM CDT, Mon May 17, 2021
JACKSONVILLE, Fla. – Healogics, a provider of wound care therapy, has announced a new $240 million equity investment, positioning the company for growth. As part of the transaction, a group of new and existing investors, led by Clayton Dubilier & Rice, Partners Group and Northwestern Mutual invested $75 million of common equity, and Marathon Asset Management invested more than $165 million in new preferred stock. “This transaction demonstrates strong support and confidence in Healogics’ business and long-term growth plan,” said David Bassin, CEO of Healogics. “With this new capital we are well-positioned to further improve our operational capacity to expand the reach of our essential care to patients in need.” Healogics has also secured a new $30 million revolving credit facility and a new $370 million first lien term loan, both led by J.P. Morgan’s Strategic Situations. The financing resulted in an extension of the company’s debt maturity schedule, with no significant maturities prior to 2025.
Comments